Last reviewed · How we verify
AND019 PO QD
At a glance
| Generic name | AND019 PO QD |
|---|---|
| Sponsor | Kind Pharmaceuticals LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AND019 PO QD CI brief — competitive landscape report
- AND019 PO QD updates RSS · CI watch RSS
- Kind Pharmaceuticals LLC portfolio CI